|
Synonyms: CTH-120 | example 2 [US9980928]
Compound class:
Synthetic organic
Comment: CTH120 is a small molecule that targets the tropomyosin receptor kinase B (TrkB), to modulate neuroplasticity. The chemical structure was revealed in the record for EU clinical trial 2025-522972-97-00. The CTH120 hydrochloride adduct is claimed as example 2 in patent US9980928 [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| CTH120 was proposed as a clinical lead as a treatment for developmental, behavioral and/or mental disorders associated with cognitive deficits such as Fragile X syndrome. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06480968 | CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction | Phase 1 Interventional | Connecta Therapeutics, S.L. | ||
| NCT07654114 | Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | Phase 2 Interventional | Connecta Therapeutics, S.L. | ||